Chief Scientific Officer
Dr. Moller brings a long history of experience in drug discovery and development to the company, including a focus on therapeutics for metabolic disorders and in the identification and evaluation of emerging technologies. Previously, Dr. Moller was Vice President of Business Development – Emerging Technology and Innovation at Eli Lilly, evaluating applications of breakthrough biology across multiple therapeutic areas. As Vice President of Endocrine and Cardiovascular Research and Clinical Investigation at Eli Lilly, Dr. Moller was responsible for discovery and early development in diverse therapeutic areas – his team contributed to several Lilly pipeline additions including dulaglutide (Trulicity). Prior to joining Eli Lilly, Dr. Moller led global discovery efforts in metabolic disorders as Vice President, Metabolic Disorders at Merck (MSD), which included oversight of the team responsible for the discovery of sitaglipitin (Januvia). Before moving to industry, Dr. Moller was on the faculty of Harvard Medical School. He completed a residency in Internal Medicine at George Washington University, received his medical degree from the University of Cincinnati and earned a B.S. from Brown University.